Effects of Bifidobacterium animalis subsp. lactis CP-9 on gut microbiota and immune functions in healthy infants
Three-month CP-9 supplementation increased intestinal Bifidobacterium abundance and improved stool characteristics in healthy infants without detected adverse events.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The double-blind RCT showed CP-9 significantly raised Bifidobacterium abundance and modulated the microbiota-mediated polyunsaturated fatty acid biosynthesis pathway. Haematological and systemic inflammatory markers remained within normal ranges. No increase in allergic or infectious events was recorded.
How it was done
Randomized, double-blind, placebo-controlled trial in healthy infants aged 6–36 months over a 3-month intervention. Safety, growth parameters, CBC, immunological markers, and faecal microbiota were assessed pre- and post-intervention.
Risk of bias
The abstract does not report sample size or quantitative effect estimates, preventing assessment of statistical power and clinical magnitude. A 3-month follow-up is insufficient to evaluate long-term immunological outcomes.
What this study does NOT prove
The study does not prove that CP-9 prevents allergic disease, infections, or confers long-term immune benefits.
In clinical practice
Safety data appear reassuring for short-term use in healthy infants; however, absence of the full text precludes evaluation of effect sizes and true clinical relevance of microbiological findings.
Limitations
The abstract does not report sample size or quantitative effect estimates, preventing assessment of statistical power and clinical magnitude. A 3-month follow-up is insufficient to evaluate long-term immunological outcomes.
Technical appendix
Version history
- 1.0 · 2026-08-02 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.